

XOMA Refinances Royalty-Based Loan Facility for \$55 Million

Date: 06/13/08

Cahill represented XOMA (US) LLC., a leader in the discovery and development of antibody therapeutics, as borrower in an amended loan facility under which it has borrowed \$55 million. The loan is secured by the royalty revenues the company receives from sales of RAPTIVA®, LUCENTIS® and CIMZIA®. The company used the proceeds of the new loan in part to repay the remaining \$22.1 million of principal outstanding under its existing loan.

Attorney

Geoffrey E. Liebmann